The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing

Introduction: MET exon 14 (METex14) skipping mutations are observed in approximately 0.9% to 4% of patients with NSCLC. This study aimed to compare the detection rates of METex14 skipping in Chinese patients with lung cancer using DNA-based next-generation sequencing (NGS) with capture-based library...

Full description

Saved in:
Bibliographic Details
Main Authors: Jia Liao, MD, Song Wu, MD, Yi Min, MD, Yiran Li, MD, Yuanhang Nie, MD, Quwen Chen, MD, Zhiliang Mao, MD, Qinglan Zong, MS, Ning Gao, MS, Ding Zhang, PhD, Weiquan Liang, MD
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:JTO Clinical and Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364325000426
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849709309402808320
author Jia Liao, MD
Song Wu, MD
Yi Min, MD
Yiran Li, MD
Yuanhang Nie, MD
Quwen Chen, MD
Zhiliang Mao, MD
Qinglan Zong, MS
Ning Gao, MS
Ding Zhang, PhD
Weiquan Liang, MD
author_facet Jia Liao, MD
Song Wu, MD
Yi Min, MD
Yiran Li, MD
Yuanhang Nie, MD
Quwen Chen, MD
Zhiliang Mao, MD
Qinglan Zong, MS
Ning Gao, MS
Ding Zhang, PhD
Weiquan Liang, MD
author_sort Jia Liao, MD
collection DOAJ
description Introduction: MET exon 14 (METex14) skipping mutations are observed in approximately 0.9% to 4% of patients with NSCLC. This study aimed to compare the detection rates of METex14 skipping in Chinese patients with lung cancer using DNA-based next-generation sequencing (NGS) with capture-based library construction and synchronous DNA-based and RNA-based NGS with amplicon-based library construction. Methods: A total of 11,330 tissue samples from 11,330 Chinese patients with lung cancer were included in the study to confirm the presence of METex14 skipping. Simultaneously, MET immunohistochemistry testing was performed on 30 patients. Results: The highest detection rate of METex14 skipping was observed in the synchronous DNA and RNA-based NGS with amplicon-based library construction, reaching 2.20%. A total of 45 different variants leading to METex14 skipping were detected at the DNA level. These variants were widely distributed across a 197–base pair DNA sequence. In the overall population, the incidence of METex14 skipping was significantly higher in individuals aged 60 years and above (p < 0.0001) and needle biopsy samples (p < 0.0001) and reported no significant association with gender and tumor location. A positive correlation was observed between microsatellite instability–high and METex14 skipping (p < 0.0001). Conclusions: The mutations causing METex14 skipping exhibit diversity in terms of variant types and are widely distributed across various genomic regions. Synchronous DNA-based and RNA-based NGS is considered the optimal method for detecting METex14 skipping. Furthermore, METex14 skipping is enriched in specific populations, including individuals aged 60 years and above, with advanced-stage disease and a microsatellite instability-high status.
format Article
id doaj-art-58ec45fc1cd04d33a3094d07b08c93a2
institution DOAJ
issn 2666-3643
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series JTO Clinical and Research Reports
spelling doaj-art-58ec45fc1cd04d33a3094d07b08c93a22025-08-20T03:15:20ZengElsevierJTO Clinical and Research Reports2666-36432025-07-016710082610.1016/j.jtocrr.2025.100826The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation SequencingJia Liao, MD0Song Wu, MD1Yi Min, MD2Yiran Li, MD3Yuanhang Nie, MD4Quwen Chen, MD5Zhiliang Mao, MD6Qinglan Zong, MS7Ning Gao, MS8Ding Zhang, PhD9Weiquan Liang, MD10The Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Guangdong, People's Republic of ChinaDepartment of Thoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Jiangsu, People's Republic of ChinaThe First Clinical Medical College, Guangdong Medical University, Guangdong, People's Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Foshan Second People's Hospital, Guangdong, People's Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Foshan Second People's Hospital, Guangdong, People's Republic of ChinaThe First Clinical Medical College, Guangdong Medical University, Guangdong, People's Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Foshan Second People's Hospital, Guangdong, People's Republic of ChinaDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, People's Republic of ChinaDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, People's Republic of ChinaDepartment of Medical Affairs, 3D Medicines Inc., Shanghai, People's Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Foshan Second People's Hospital, Guangdong, People's Republic of China; Corresponding author. Address for correspondence: Weiquan Liang, MD, Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Foshan (Affiliated Foshan Hospital of Southern Medical University), Weiguo Lu 78, Foshan City, Guangdong Province 528000, People's Republic of China.Introduction: MET exon 14 (METex14) skipping mutations are observed in approximately 0.9% to 4% of patients with NSCLC. This study aimed to compare the detection rates of METex14 skipping in Chinese patients with lung cancer using DNA-based next-generation sequencing (NGS) with capture-based library construction and synchronous DNA-based and RNA-based NGS with amplicon-based library construction. Methods: A total of 11,330 tissue samples from 11,330 Chinese patients with lung cancer were included in the study to confirm the presence of METex14 skipping. Simultaneously, MET immunohistochemistry testing was performed on 30 patients. Results: The highest detection rate of METex14 skipping was observed in the synchronous DNA and RNA-based NGS with amplicon-based library construction, reaching 2.20%. A total of 45 different variants leading to METex14 skipping were detected at the DNA level. These variants were widely distributed across a 197–base pair DNA sequence. In the overall population, the incidence of METex14 skipping was significantly higher in individuals aged 60 years and above (p < 0.0001) and needle biopsy samples (p < 0.0001) and reported no significant association with gender and tumor location. A positive correlation was observed between microsatellite instability–high and METex14 skipping (p < 0.0001). Conclusions: The mutations causing METex14 skipping exhibit diversity in terms of variant types and are widely distributed across various genomic regions. Synchronous DNA-based and RNA-based NGS is considered the optimal method for detecting METex14 skipping. Furthermore, METex14 skipping is enriched in specific populations, including individuals aged 60 years and above, with advanced-stage disease and a microsatellite instability-high status.http://www.sciencedirect.com/science/article/pii/S2666364325000426Lung cancerSecond generation sequencingMETex14 skippingAmplicon-based library constructionCapture-based library construction
spellingShingle Jia Liao, MD
Song Wu, MD
Yi Min, MD
Yiran Li, MD
Yuanhang Nie, MD
Quwen Chen, MD
Zhiliang Mao, MD
Qinglan Zong, MS
Ning Gao, MS
Ding Zhang, PhD
Weiquan Liang, MD
The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
JTO Clinical and Research Reports
Lung cancer
Second generation sequencing
METex14 skipping
Amplicon-based library construction
Capture-based library construction
title The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
title_full The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
title_fullStr The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
title_full_unstemmed The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
title_short The Landscape of MET Exon 14 Skipping Mutations in Patients With Lung Cancer Identified by Next-Generation Sequencing
title_sort landscape of met exon 14 skipping mutations in patients with lung cancer identified by next generation sequencing
topic Lung cancer
Second generation sequencing
METex14 skipping
Amplicon-based library construction
Capture-based library construction
url http://www.sciencedirect.com/science/article/pii/S2666364325000426
work_keys_str_mv AT jialiaomd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT songwumd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT yiminmd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT yiranlimd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT yuanhangniemd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT quwenchenmd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT zhiliangmaomd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT qinglanzongms thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT ninggaoms thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT dingzhangphd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT weiquanliangmd thelandscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT jialiaomd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT songwumd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT yiminmd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT yiranlimd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT yuanhangniemd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT quwenchenmd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT zhiliangmaomd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT qinglanzongms landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT ninggaoms landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT dingzhangphd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing
AT weiquanliangmd landscapeofmetexon14skippingmutationsinpatientswithlungcanceridentifiedbynextgenerationsequencing